Advait Upadhyaya

Advait Upadhyaya

Auto-generated profile, based on publicly available information

Advait Upadhyaya

Wingate Institute, Blizard Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry Blizard Institute, London, UK

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2025 in Frontline Gastroenterology
Verified
Journal Article
Closed access
PDF file
AUAdvait Upadhyaya
Advait Upadhyaya
RTRabia Topan
Rabia Topan
SPShraya Pandya
Shraya Pandya
SWSarah Williams
Sarah Williams
KFKonstantinos Fragkos
Konstantinos Fragkos
AFAsma Fikree
Asma Fikree
Background/objective Disorders of Gut–Brain interactions (DGBI), for example, Functional Dyspepsia (FD) or Irritable Bowel syndrome (IBS), are common in patients with hypermobile Ehlers-Danlos syndrome/hypermobile spectrum disorder (hEDS/HSD). DGBI is associated with significant healthcare use—how this applies to patients with coexisting hEDS/HSD is unknown. Design A cross-sectional study was performed. Patients recruited from tertiary neurogastroenterology clinics and from Ehlers-Danlos Support UK completed questionnaires, characterising their demographic, healthcare data and expenses, over 6 months (July 2021–January 2022) and their Rome IV diagnoses. National Health Service (NHS) unit costs were used. Healthcare use and costs were compared across and between DGBI and non-DGBI subgroups. Regression analysis was performed to determine predictors of costs. p<0.005 was considered significant. Results Median age of the 660 respondents was 39 (IQR: 29–50) years; 96.1% had a DGBI. 13.6% had IBS, 29.9% had FD, 32.1% had IBS and FD, 24.4% had neither. Patients with DGBI had high healthcare use and large healthcare costs; £3388.79/6 months, mostly attributed to consultations (36.4%) and admissions (22.7%). Costs per patient (pp) were at least double in any group with FD (£4026.53–£4297.30pp) compared with those without (£1372.49–£1979.36pp), p£20 000 pp/6 months). Predictors of rising costs were FD, non-gastrointestinal comorbidities, lower body mass index, positive avoidant/restrictive food intake disorders screen, having an altered diet, polypharmacy, visits to different healthcare professionals and tertiary neurogastroenterology recruitment. Conclusions It is imperative to develop cost-effective multidisciplinary services for hEDS/HSD patients with FD, particularly in the current fiscal climate, as they have significant healthcare use and costs.